Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases
An Observation, Open Label Study of Alpharadin (Radium 223) in Patients With Castrate Resistant Prostate Cancer Bone Metastases
Sponsor: Bayer
This NA trial investigates Prostate Cancer and is currently completed. Bayer leads this study, which shows 15 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
-
Dec 2022 — Jan 2023 [monthly]
Completed NA
-
Mar 2022 — Dec 2022 [monthly]
Completed NA
▶ Show 10 earlier versions
-
Jan 2021 — Mar 2022 [monthly]
Completed NA
-
Dec 2020 — Jan 2021 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jan 2020 — Dec 2020 [monthly]
Active Not Recruiting NA
-
Jun 2019 — Jan 2020 [monthly]
Active Not Recruiting NA
-
Jun 2018 — Jun 2019 [monthly]
Active Not Recruiting NA
-
Aug 2017 — Jun 2018 [monthly]
Active Not Recruiting NA
Phase: EARLY_PHASE1 → NA
-
Jul 2017 — Aug 2017 [monthly]
Active Not Recruiting EARLY_PHASE1
-
Jun 2017 — Jul 2017 [monthly]
Active Not Recruiting EARLY_PHASE1
Phase: NA → EARLY_PHASE1
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- M.D. Anderson Cancer Center
- Prostate Cancer Foundation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Houston, United States